<?xml version="1.0" encoding="UTF-8"?>
<p id="P6">Allogeneic stem cell transplantation (alloSCT) is a potentially curative therapeutic option for patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). Disease relapse occurs in 35% to 45% of patients after alloSCT and is the most frequent cause of treatment failure and mortality [
 <xref rid="R1" ref-type="bibr">1</xref>â€“
 <xref rid="R4" ref-type="bibr">4</xref>]. Moreover, relapse after alloSCT is associated with poor prognosis despite salvage chemotherapy, donor lymphocyte infusions, and/or second transplants [
 <xref rid="R4" ref-type="bibr">4</xref>].
</p>
